Financial reports
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
12 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
14 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
16 Apr 24
8-K
Results of Operations and Financial Condition
12 Mar 24
8-K
Clearside Biomedical Announces Pricing of $15 Million Registered
8 Feb 24
8-K
Entry into a Material Definitive Agreement
1 Feb 24
8-K
Entry into a Material Definitive Agreement
28 Dec 23
8-K
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
13 Nov 23
8-K
Entry into a Material Definitive Agreement
3 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Sep 23
8-K
Results of Operations and Financial Condition
14 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
22 Jun 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
8 Feb 24
S-3
Shelf registration
12 May 23
S-8
Registration of securities for employees
12 May 23
S-8
Registration of securities for employees
12 May 22
S-8
Registration of securities for employees
17 May 21
424B5
Prospectus supplement for primary offering
7 Jan 21
424B5
Prospectus supplement for primary offering
22 May 20
S-3/A
Shelf registration (amended)
19 May 20
S-8
Registration of securities for employees
8 May 20
S-3
Shelf registration
8 May 20
Proxies
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
PRE 14A
Preliminary proxy
19 Apr 22
DEFA14A
Additional proxy soliciting materials
28 Apr 21
DEF 14A
Definitive proxy
28 Apr 21
DEFA14A
Additional proxy soliciting materials
29 Apr 20
Other
EFFECT
Notice of effectiveness
22 May 23
UPLOAD
Letter from SEC
17 May 23
CORRESP
Correspondence with SEC
17 May 23
EFFECT
Notice of effectiveness
26 May 20
CORRESP
Correspondence with SEC
20 May 20
CORRESP
Correspondence with SEC
18 May 20
UPLOAD
Letter from SEC
14 May 20
EFFECT
Notice of effectiveness
21 Jan 20
CORRESP
Correspondence with SEC
15 Jan 20
UPLOAD
Letter from SEC
15 Jan 20
Ownership
4
Anthony S Gibney
19 Apr 24
4
Anthony S Gibney
16 Apr 24
3
Anthony S Gibney
16 Apr 24
4
Ngai Hang Victor Chong
20 Mar 24
4
Ngai Hang Victor Chong
18 Mar 24
3
Ngai Hang Victor Chong
18 Mar 24
4
BRADFORD T WHITMORE
9 Feb 24
4
GEORGE M LASEZKAY
19 Jan 24
4
Charles A. Deignan
19 Jan 24
144
Notice of proposed sale of securities
19 Jan 24